On March 29th, the FDA approved the Narcan nasal spray for over-the-counter sales. It is the first naloxone product approved for use without a prescription. In this episode of The Top Line, Fierce Pharma staff writer Fraiser Kansteiner launches a mini-series to explore what that means for the opioid epidemic. The series will tackle questions about using the product, its accessibility and whether the move will save lives.

To learn more about the topics in this episode: 
Emergent makes history with first FDA nod for over-the-counter naloxone
Teva, Sandoz have launched Narcan generics, but Emergent's branded option should still thrive: analysts
Adapt tests ads urging opioid users' loved ones to stock Narcan at home
Eyeing $1B in annual sales, Emergent BioSolutions to buy Narcan maker Adapt for $735M
Ahead of next month's FDA decision, Emergent aces AdComm for over-the-counter Narcan nod

The Top Line is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

On March 29th, the FDA approved the Narcan nasal spray for over-the-counter sales. It is the first naloxone product approved for use without a prescription. In this episode of The Top Line, Fierce Pharma staff writer Fraiser Kansteiner launches a mini-series to explore what that means for the opioid epidemic. The series will tackle questions about using the product, its accessibility and whether the move will save lives.
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercepharma.com/manufacturing/emergent-makes-history-first-fda-nod-over-counter-naloxone" data-cke-saved-href="https://www.fiercepharma.com/manufacturing/emergent-makes-history-first-fda-nod-over-counter-naloxone">Emergent makes history with first FDA nod for over-the-counter naloxone</a></li>
<li><a href="https://www.fiercepharma.com/pharma/teva-and-sandoz-s-generics-have-launched-but-emergent-s-narcan-still-likely-to-thrive" data-cke-saved-href="https://www.fiercepharma.com/pharma/teva-and-sandoz-s-generics-have-launched-but-emergent-s-narcan-still-likely-to-thrive">Teva, Sandoz have launched Narcan generics, but Emergent's branded option should still thrive: analysts</a></li>
<li><a href="https://www.fiercepharma.com/marketing/adapt-launches-regional-test-campaigns-to-encourage-opioid-users-loved-ones-to-keep" data-cke-saved-href="https://www.fiercepharma.com/marketing/adapt-launches-regional-test-campaigns-to-encourage-opioid-users-loved-ones-to-keep">Adapt tests ads urging opioid users' loved ones to stock Narcan at home</a></li>
<li><a href="https://www.fiercepharma.com/pharma/eyeing-1b-annual-sales-emergent-biosolutions-to-buy-narcan-maker-adapt-for-735m" data-cke-saved-href="https://www.fiercepharma.com/pharma/eyeing-1b-annual-sales-emergent-biosolutions-to-buy-narcan-maker-adapt-for-735m">Eyeing $1B in annual sales, Emergent BioSolutions to buy Narcan maker Adapt for $735M</a></li>
<li><a href="https://www.fiercepharma.com/pharma/ahead-next-months-fda-decision-emergent-aces-adcom-over-counter-narcan" data-cke-saved-href="https://www.fiercepharma.com/pharma/ahead-next-months-fda-decision-emergent-aces-adcom-over-counter-narcan">Ahead of next month's FDA decision, Emergent aces AdComm for over-the-counter Narcan nod</a></li>
</ul>
The Top Line is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement